616.234.5000

Therapeutics

Autophagy inhibitors

These potent autophagy inhibitors show strong promise for significantly reducing tumor survival and progression.

Conserved diaphanous-related formains autoregulatory domain (DAD) peptides

These peptides are derived from diaphanous-related formins that activate actin polymerization in mammalian cells. Potential applications include the following uses: as a novel anti-cancer therapeutic drug, as a research tool to study cell signaling, structure and physiology, as a novel in vivo model for testing the biochemical activity of small GTPases, and as a reporter for intracellular activation of small GTPases.

Expression and purification of functional norrin protein

This method of norrin protein production makes large-scale protein generation more cost effective, increasing the viability of using norrin as an anti-angiogenic therapeutic agent.

Human MET antibody fragments

These human Fab and scFv fragments are specific to the human MET extracellular domain and are internalized upon receptor binding. Potential applications include radioimmunotherapy and use as a carrier for delivering potent chemotherapeutics to MET-expressing tumors.

MET siRNA viral vectors

MET siRNA inhibits cancer cell growth, invasion and tumorigenicity. This technology could serve as a potential alternative to chemotherapy as well as a research tool to study MET-associated signaling pathways and mechanisms.

Parathyroid hormone (PTH) and PTH-related protein (PTHrP) peptides

These innovative peptides bind and activate the PTH/PTHrP receptor (PTH1R). Potential applications include use as a tool for designing selective PTH1R-binding molecules and as a treatment option for osteoporosis.